VNOV (VitaNova Life Sciences) ROCE %: -21.92% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VNOV VitaNova Life Sciences Corp VNOV
51 GF Score
Price $1.38
GF Value $5.95
! 1 Warning Sign
View Full Analysis

What is VitaNova Life Sciences ROCE %?

VitaNova Life Sciences VNOV 51 ROCE % is -21.92% as of Apr. 2026. GuruFocus rates VNOV with a GF Score™ of 51/100 and a GF Value™ of $5.95. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. VitaNova Life Sciences's annualized ROCE % for the quarter that ended in Apr. 2026 was -21.92%.

VitaNova Life Sciences  (OTCPK:VNOV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

VitaNova Life Sciences ROCE % Related Terms

VitaNova Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for VitaNova Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VitaNova Life Sciences ROCE % Chart

VitaNova Life Sciences Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 41.32 81.58 0.35

VitaNova Life Sciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 287.00 -6.79 21.06 10.02 -21.92
VNOV
51GF Score
VitaNova Life Sciences Corp VNOV
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VitaNova Life Sciences ROCE % Calculation

VitaNova Life Sciences's annualized ROCE % for the fiscal year that ended in Apr. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2026 )  (A: Apr. 2025 )(A: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2026 )  (A: Apr. 2025 )(A: Apr. 2026 )
=0.007/( ( (2.256 - 0.348) + (2.447 - 0.396) )/ 2 )
=0.007/( (1.908+2.051)/ 2 )
=0.007/1.9795
=0.35 %

VitaNova Life Sciences's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=-0.428/( ( (2.312 - 0.458) + (2.447 - 0.396) )/ 2 )
=-0.428/( ( 1.854 + 2.051 )/ 2 )
=-0.428/1.9525
=-21.92 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -21.92% mean?
VitaNova Life Sciences (VNOV) has a ROCE % of -21.92% as of Apr. 2026.
Is VitaNova Life Sciences' ROCE % too high?
VitaNova Life Sciences' current ROCE % is -21.92%. Overall, VitaNova Life Sciences has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does VitaNova Life Sciences' ROCE % compare to HKPD and COSM?
VitaNova Life Sciences' ROCE % of -21.92% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VitaNova Life Sciences's current ROCE % is -21.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VitaNova Life Sciences stock overvalued right now?
VitaNova Life Sciences (VNOV) has a current ROCE % of -21.92%. The stock's GF Value™ is $5.95, compared to a current price of $1.38 — trading 76.8% below its estimated fair value. The current ROCE % is -21.92%. VitaNova Life Sciences' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For VitaNova Life Sciences (VNOV), the current ROCE % is -21.92% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VitaNova Life Sciences (VNOV) Overvalued in 2026?

Based on GuruFocus' analysis, VitaNova Life Sciences stock appears to be undervalued. The current stock price of $1.38 is trading 76.8% below its estimated GF Value™ of $5.95.

Key valuation signals for VNOV:

  • ROCE %: -21.92%
  • GF Value™: $5.95 vs. price of $1.38 (76.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the VNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VitaNova Life Sciences Business Description

Address 30 E Broadway, Suite 603, New York, NY, USA, 10002
VitaNova Life Sciences Corp, formerly Yijia Group Corp provides business consulting services to domestic and international customers. The Company provides consulting services to its clients with regards to funding and other financial matters.The company's operating segments are The consulting services Segment mainly provides consulting advisory services in management, business, accounting and finance; and the Healthcare Segment mainly provides healthcare products and health consultation services to customers. The sale and distribution of healthcare products, such as Nicotinamide Riboside capsules, has only one performance obligation under the fixed-fee arrangements. and the majority of its revenue generates from Sales of healthcare products.
51GF Score

Get the complete analysis for VNOV

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$5.95
GF Value